The Health IT Policy Committee (HITPC) adopted recommendations from its Consumer Empowerment Workgroup on patient-generated health data (PGHD) at its December meeting and is expected to finalize its complete Stage 3 recommendations in February.
The Health IT Policy Committee (HITPC) adopted recommendations from its Consumer Empowerment Workgroup on patient-generated health data (PGHD) at its December meeting and is expected to finalize its complete Stage 3 recommendations in February.
The committee reaffirmed that its objective--"patients [should] have the ability to electronically submit patient-generated health information"--should be part of Meaningful Use Stage 3, according to a report from a technical expert panel convened at the request of the Office of the National Coordinator.
This data, which could be submitted by a patient, caregiver or other designee, "could be an observation, a test result, a device finding, a confirmation or a change/correction/addition of data in the patient's existing health record"--data collected outside the clinical visit, explains a blog post at HealthITBuzz.
"As 2013 draws to a close, we are pleased to report that a lot of progress has made," writes Mary Jo Deering, senior policy advisor in the Office of Policy and Planning, of the ONC's efforts to better understand and implement policies concerning this data.
Read the full story here: http://bit.ly/19FezPe
Source: Fierce Health IT
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More